ATE285253T1 - Beta-interferon zur behandlung von immunerkrankungen - Google Patents

Beta-interferon zur behandlung von immunerkrankungen

Info

Publication number
ATE285253T1
ATE285253T1 AT01103580T AT01103580T ATE285253T1 AT E285253 T1 ATE285253 T1 AT E285253T1 AT 01103580 T AT01103580 T AT 01103580T AT 01103580 T AT01103580 T AT 01103580T AT E285253 T1 ATE285253 T1 AT E285253T1
Authority
AT
Austria
Prior art keywords
treatment
immune diseases
beta interferon
interferon
beta
Prior art date
Application number
AT01103580T
Other languages
English (en)
Inventor
Serge Braun
Original Assignee
Transgene Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transgene Sa filed Critical Transgene Sa
Application granted granted Critical
Publication of ATE285253T1 publication Critical patent/ATE285253T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AT01103580T 2000-02-23 2001-02-20 Beta-interferon zur behandlung von immunerkrankungen ATE285253T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00440053 2000-02-23
US24608900P 2000-11-07 2000-11-07

Publications (1)

Publication Number Publication Date
ATE285253T1 true ATE285253T1 (de) 2005-01-15

Family

ID=26073631

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01103580T ATE285253T1 (de) 2000-02-23 2001-02-20 Beta-interferon zur behandlung von immunerkrankungen

Country Status (10)

Country Link
US (1) US6906041B2 (de)
EP (1) EP1133997B1 (de)
JP (1) JP2001270840A (de)
AT (1) ATE285253T1 (de)
AU (1) AU780270B2 (de)
CA (1) CA2334520C (de)
DE (1) DE60107888T2 (de)
DK (1) DK1133997T3 (de)
ES (1) ES2234714T3 (de)
PT (1) PT1133997E (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020197235A1 (en) * 2000-11-03 2002-12-26 Moran Stanford Mark Method for short-term and long-term drug dosimetry
JP4508638B2 (ja) * 2001-08-01 2010-07-21 アネコバ ソシエテ アノニム 子宮内器具、該器具の作成方法、および子宮腔内に活性要素を挿入する方法
DE10148417A1 (de) * 2001-09-29 2003-04-17 Andreas Schwarting Verwendung von Interferon-ß zur Therapie des systemischen Lupus erythematodes
EP1539960B1 (de) * 2002-09-09 2010-04-28 Hanall Pharmaceutical Co., Ltd. Protease-resistente modifizierte interferon alpha polypeptide
CA2499533A1 (en) * 2002-09-26 2004-04-08 Pfizer Products Inc. Use of excipients to increase dna uptake by swine muscle cells
GB0405634D0 (en) 2004-03-12 2004-04-21 Univ Southampton Anti-virus therapy for respiratory diseases
CN101102739B (zh) * 2005-01-12 2017-02-08 比奥根Ma公司 运输干扰素‑β的方法
US8716021B2 (en) * 2005-09-07 2014-05-06 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of replicators to prevent gene silencing
WO2007110231A2 (en) * 2006-03-28 2007-10-04 Nautilus Biotech, S.A. MODIFIED INTERFERON-β (IFN-β) POLYPEPTIDES
CA2685596A1 (en) * 2007-05-02 2008-11-13 Ambrx, Inc. Modified interferon beta polypeptides and their uses

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5703055A (en) * 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US6359054B1 (en) * 1994-11-18 2002-03-19 Supratek Pharma Inc. Polynucleotide compositions for intramuscular administration

Also Published As

Publication number Publication date
JP2001270840A (ja) 2001-10-02
PT1133997E (pt) 2005-04-29
DE60107888D1 (de) 2005-01-27
DE60107888T2 (de) 2005-12-15
AU2306801A (en) 2001-08-30
EP1133997A2 (de) 2001-09-19
DK1133997T3 (da) 2005-04-18
CA2334520C (en) 2008-12-23
EP1133997B1 (de) 2004-12-22
EP1133997A3 (de) 2002-06-05
US6906041B2 (en) 2005-06-14
ES2234714T3 (es) 2005-07-01
CA2334520A1 (en) 2001-08-23
AU780270B2 (en) 2005-03-10
US20020076399A1 (en) 2002-06-20

Similar Documents

Publication Publication Date Title
ATE315938T1 (de) 4'-substituierte nukleoside zur behandlung von hepatitis-c-virus-vermittelten erkrankungen
DE69033040T2 (de) Verfahren zur Herstellung von biologisch aktivem Protein (z.B. TGF)
DE50206657D1 (de) Pharmazeutische zusammensetzung zur behandlung von multiple sklerose
DE60230425D1 (de) Phenethanolamin-derivate zur behandlung von erkrankungen der atemwege
DE60325209D1 (de) Diarylharnstoffderivate, die sich zur behandlung von proteinkinaseabhängigen krankheiten eignen
DE69929310D1 (de) Tumorassoziierte antigenderivate der mage-familie, nukleinsäuresequenzen die dafür kodieren, zur herstellung von fusionsproteinen und zusammensetzungen zur impfung
DE60126321D1 (de) Gelsystem zur ocularen verabreichung von arzneimitteln
DE602004028763D1 (de) Te zur behandlung von virenerkrankungen
ATE447947T1 (de) Pharmazeutische zubereitungen zur behandlung von insulinresitenz
DE60225666D1 (de) Verfahren zur herstellung von pharmazeutischen zusammensetzungen enthaltend epothilon-analoga zur krebsbehandlung
ATE318590T1 (de) Arzneimittelkombinationen (z.b. chlorpromazin und pentamidin) zur therapie von neoplastischen erkrankungen
DE60137631D1 (de) Ireovirus antikörpern zur behandlung von ras-vermittelten, proliferativen erkrankungen
DE60123238D1 (de) Zusammensetzungen zur behandlung von autoimmunkrankheiten
LU93259I2 (fr) LETIFEND (Protein Q)
ES2168361T3 (es) Secuencias de adn para metaloproteasas de la matriz, su preparacion y empleo.
DE60204466D1 (de) Integrinhemmer zur behandlung von augenkrankheiten
DE60027209D1 (de) Arzneimittel enthaltend hydroxyapatite zur behandlung von knochengewebserkrankungen
ATE285253T1 (de) Beta-interferon zur behandlung von immunerkrankungen
DE60218375D1 (de) Pharmazeutische Zusammensetzung zur Behandlung gynäkologischer Erkrankungen
DE50013843D1 (de) Arzneimittel zur behandlung von darmerkrankungen
IT1318514B1 (it) Formulazioni contenenti un farmaco glucocorticosteroide per iltrattamento di patologie broncopolmonari.
ATE107859T1 (de) Verwendung von antiprogestomimetika zur stimulierung des eisprungs.
DE60216457D1 (de) Carbamate verbindungen zur behandlung oder verhutung von psychotischen krankheiten
DE69837148D1 (de) Chimäre proteine zur behandlung von diabetes
ATE251167T1 (de) Oxazinocarbazole zur behandlung von cns- erkrankungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1133997

Country of ref document: EP

EEIH Change in the person of patent owner
REN Ceased due to non-payment of the annual fee